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Chikungunya (CHIKV), Dengue (DENV) and Zika (ZIKV) viruses have been of growing public 
health concern in Latin America. Increasing incidence of new infections alongside the continuing lack 
of licenced antivirals or vaccines have contributed to a rising burden of disease in populations and cost 
for healthcare systems. These burdens are further exacerbated due to the difficulty of achieving 
accurate diagnosis in settings where these viruses co-circulate. Thus, the aim of this research was to 
study co-circulating CHIKV, DENV and ZIKV in Latin America, particularly in relation to co-infections 
and the accurate identification of specific arbovirus infections.  
 First, a systematic review of the published literature on ZIKV co-infections was conducted, 
assessing the co-infection frequency among ZIKV infected cases and the impact of co-infection on the 
clinical presentation of ZIKV. Second, the co-circulation of CHIKV and ZIKV in a cohort of pregnant 
women in Recife, Brazil from 2015-2017 was described and the potential to differentiate between 
infections at symptom presentation was assessed. 
 The systematic review's main findings showed that the most frequent ZIKV co-infections 
occurred with CHIKV and DENV, and in some circumstances occurred in up to half of the ZIKV 
infections. Additionally, co-infection did not seem to affect the mild clinical presentation of ZIKV 
infections. However, the review was not able to assess a potential increase of complications associated 
with ZIKV co-infections compared to ZIKV mono-infections. Furthermore, the analysis of the cohort 
study showed that CHIKV and ZIKV infection were distinguishable upon clinical presentation in 
pregnant women.  
 Our findings on ZIKV co-infections and the clinical presentation of ZIKV and CHIKV infected 
pregnant women contribute to improved patient management in settings of arbovirus co-circulation, 
through aiming to facilitate clinical diagnosis and guide laboratory testing, in order to administer 
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1. CHAPTER 1: LITERATURE REVIEW 
 In this chapter, I provided a brief outline of the literature on arthropod-borne viruses 
(arboviruses). The key areas that are summarized are the epidemiology, transmission, clinical 
presentation, diagnosis, treatment, co-infection and infection in pregnancy of arboviruses, in particular 
of Chikungunya virus (CHIKV), Dengue virus (DENV) and Zika virus (ZIKV). Finally, the knowledge 
gaps which have driven this research are highlighted.       
 Arboviruses are a growing global public health concern1. This is provoked by the rising 
contribution of arbovirus infections to global disability and mortality over the past 50 years2,3. 
Furthermore, over the past 20 years arboviruses have been increasingly occurring either in an endemic 
manner or in explosive emergent and re-emergent epidemics in Latin America4,5. CHIKV, DENV and 
ZIKV are the arboviruses of greatest recent public health concern in Latin America6. Their rising public 
health relevance is due to their increasing prevalence and ongoing co-circulation over the past 20 
years, and to the continuing lack of optimal tools for prevention (e.g., vaccines) and treatment (e.g., 
antivirals) of infections. The three arboviruses share the same mosquito vectors of the Aedes species 
(e.g., Aedes aegypti, Aedes albopictus), leading them to occur in highly overlapping geographic areas, 
predominately in urban settings. Furthermore, prevention of CHIKV, DENV and ZIKV infections is 
challenging as mosquito bites cannot be entirely avoided. Avoiding mosquito bites is especially 
challenging in low socio-economic status households due to lack of household protective measures, 
including unscreened houses and the absence of air-conditioning7,8. CHIKV, DENV and ZIKV have also 
been described as sharing similar clinical symptoms, which therefore makes differential diagnosis, 
supportive care and prognosis difficult, negatively impacting the health outcomes of patients and 
pregnancies. Arbovirus infections are generally asymptomatic and mild, typically presenting with fever 
and rash1,9. However, various neurological complications have been reported to result from arboviral 
infections10. 
1.1 Arboviruses 
The defining feature of all arboviruses is their transmission between an arthropod vector and a 




animals such as non-human primates (e.g., monkeys), birds, horses and rodents after having been 
transmitted by an arthropod vector, such as a mosquito or tick. To note, although CHIKV, ZIKV and 
DENV can circulate in sylvatic cycles, they are not dependent on them12. Additionally, arboviruses are 
primarily RNA viruses11. The high mutation rate of RNA viruses may be advantageous when these 
viruses alternate cycles of replication between very diverse environments such as invertebrate 
arthropods and vertebrates11. Arboviruses are taxonomically diverse, mainly originating from the 
families of Flaviviridae, Togaviridae and Bunyaviridae10. The geographic distribution of DENV and ZIKV 
from the family of Flaviviridae and CHIKV from the family of Togaviridae almost entirely overlap (Figure 
1)10, as the study by Charlier and colleagues did not display ZIKV cases in Asian countries between 
2010-2019, such as those reported in Bangladesh, Cambodia, China, India, Malaysia, Indonesia, Japan, 
Maldives, Lao, Korea, Pakistan, Singapore, Myanmar, Philippines, Taiwan, Thailand and Vietnam13.   
Figure 1: World distribution of arboviruses. Taken from Charlier et al. (2017)10. To highlight, 
in A the distribution of Zika virus is marked in light blue surrounded with a dashed line, and the 




The increasing global prevalence of arboviruses is caused by a combination of factors. These 
factors include: 
• Growing urbanisation and deforestation, which enables increased vector-host contact11.  
• Expanded human movement, which means that mosquito eggs and infected humans will spread to 
other previously unaffected areas that will in turn allow the vector to spread and will present 
previously uninfected mosquitos to become infected vectors14.  
• Poor sanitation conditions, such as no access to running water, which results in the population 
storing water, that consequently serves as additional mosquito breeding-sites, complicates vector 
control14. 
• Rising insecticide resistance of mosquitoes additionally challenges measures to control vector 
populations14.  
• Changing climate and climatic events, such as El-Niño, assist vector amplification and expansion 
beyond tropical latitudes11.  
The changing global climate and human demography also enhances the potential of new arboviruses 
emerging from sylvatic cycles to cause disease in animals and humans.     
 In the last 20 years, CHIKV, DENV and ZIKV have been the arboviruses of increasing public 
health concern in Latin America6. Their growing prevalence is causing a rising burden across the whole 
population15. In order to explain how CHIKV, DENV and ZIKV managed to spread almost globally, I 
describe their epidemiology below. 
1.2 Epidemiology of CHIKV 
 CHIKV is an Alphavirus from the family of Togaviridae, which was first identified in Tanzania in 
195316. The name “Chikungunya” originates from a word used by the southeast Tanzanian Makonde 
ethnic group, which directly translated means “that which bends up”, describing the patient’s position 
when suffering from severe joint pains17. CHIKV, has four different genotypes: Asian, West African, 
East/Central/South African, and Indian Ocean18. The virus has a long history of emergence in urban 
transmission cycles, enzootic (i.e., circulating in an animal population) and sylvatic foci in sub-Saharan 




East Asia, and Europe, where it is transmitted by Aedes albopictus. The most recent CHIKV outbreak 
started in Latin America in 201320-29. In 2016, there was evidence of CHIKV transmission in 94 
countries worldwide30. To date, about 1.3 billion people are estimated to be at risk of CHIKV 
infection30,31. This estimate is based on the population living in areas most environmentally suitable for 
mosquitoes, which are competent of CHIKV transmission30,31. 
1.3 Epidemiology of DENV 
DENV is a Flavivirus, and consists of four different serotypes (DENV-1,-2,-3,-4). Historical 
reports describe dengue-like outbreaks in Latin America 400 years ago32. The name "Dengue" is  
thought to have originated from the Swahili term "ki-denga pepo" translating to "a disease 
characterized by the sudden cramp-like seizures caused by an evil spirit"33. DENV was first isolated in 
Japan in 1943 and then in Hawaii in 194534. Various outbreaks took place simultaneously, and cases 
were reported that presented with dengue-like symptoms from India to the Pacific islands35. World 
War II is documented to be the origin of the global expansion of DENV36. Thousands of DENV cases 
within the Japanese and allied forces, in addition to the movement of their troops and war materials, 
enabled the virus and main vector Aedes aegypti to spread to most areas of Asia and the Pacific, where 
it had not been prevalent before36. In Latin America, an Aedes aegypti eradication program effectively 
eliminated this mosquito type in 23 countries during the 1950s and 1960s37,38. Although, the eradication 
program was initially aimed at the epidemic of the Yellow fever virus (YFV) it also effectively controlled 
the ongoing DENV epidemics37.  However, the termination of this program in the 1970s led to the 
reestablishment of Aedes aegypti in the tropical areas of Latin America36. The program’s termination 
along with increased urbanisation and the new introduction of DENV-3 in 1963, DENV-1 in 1977, 
DENV-4 from Asia in 1981, resulted in all four serotypes becoming endemic in Latin America36. In 
2012, evidence revealed that 3.97 billion people in 128 countries were living with the risk of DENV 
infection39. This estimate, similarly to that of the population at risk of CHIKV infections, is based on 
the population living in areas most environmentally suitable for mosquitoes, which are competent of 
DENV transmission. However, in comparison to the risk of CHIKV infections measured at a 5km 




The actual number of DENV cases is believed to be underreported and many cases are misclassified 
due to similar clinical presentation of other febrile disease-causing pathogens23. A report in 2013 
estimated that there were 390 million DENV infections per year worldwide (95% credible interval 
284–528 million), of which 96 million (95% credible interval 67–136 million) manifested any 
symptomatic disease40. 
1.4 Epidemiology of ZIKV 
During a YFV surveillance study, ZIKV was first isolated from the serum of a sentinel rhesus 
macaque in 1947 in the Ziika forest in Uganda, from which the virus's name originates. Subsequently, 
the Flavivirus ZIKV was isolated in Uganda from an Aedes africanus mosquito in 1948 and from humans 
in 195241-44. In the following 60 years very few cases of ZIKV were diagnosed in Africa and Asia, leading 
to the assumption that ZIKV infection was mostly asymptomatic or caused mild febrile illness or was 
in very low transmission44-49. The first ZIKV disease outbreak was documented in 2007 on Yap Islands 
in the South Pacific, where approximately 73% of the population were infected (i.e., more than 900 
infected inhabitants)50. After increasing cases throughout the Pacific Islands, the second largest ZIKV 
outbreak followed in French Polynesia in 2013-2014. Here, for the first time retrospective reports 
were presented of neurological complications in adults, such as Guillain-Barré syndrome (GBS)51. 
There is one ZIKV serotype (i.e., classification based on viral cell surface antigen) with two ZIKV 
lineages (African and Asian) and three ZIKV genotypes (i.e., a classification based on the viral genetic 
constitution) (West African, East African, and Asian)45,52,53. Both outbreaks, on Yap Island and in French 
Polynesia were caused by the Asian ZIKV lineage54,55. Although phylogenetic studies indicate virus 
introduction as early as 2013, the first confirmed case of ZIKV infection in the Americas, also caused 
by the Asian lineage, was reported in Northeast Brazil in May 201556,57. ZIKV rapidly spread across 
Brazil, causing up to 1.5 million cases by  early 201658. The outbreak continued until late 2017, 




1.5 Transmission of CHIKV, DENV and ZIKV 
 There are several different routes of transmission of the arboviruses CHIKV, DENV and ZIKV 
(Table 1). The first transmission route is by mosquito bite1. CHIKV, DENV and ZIKV share the same 
vector, the Aedes spp. mosquitoes1. Notably, all arboviruses that experienced the most striking 
emergence in the 21st century in Latin America (i.e., ZIKV, DENV and CHIKV) are transmitted in 
urban or peri-urban (i.e., areas immediately surrounding cities) areas by the Aedes spp. mosquitoes, 
and mainly by Aedes aegypti1. Aedes aegypti is now predicted to be present in almost all tropical and 
subtropical areas (Figure 2), and over 3 billion people are currently living in regions where Aedes is 
present62. 
After an incubation period of the arbovirus within the mosquito Aedes aegypti, which typically 
ranges from 3 to 14 days, a female mosquito will develop a persistent salivary gland infection and 
generally remains infectious for a lifetime63. The main source of virus for uninfected mosquitoes is 
infected symptomatic and asymptomatic humans, as they are the main carriers and multipliers of the 
virus. All three viruses have also been reported to rarely be transmitted by blood transfusion, and 
ZIKV is the only Flavivirus to date that has been confirmed to be sexually transmitted36,64,65. Further, 
mother-to-child transmission has been reported for all three arboviruses, but the transmission 
frequency and mechanisms seem to differ between CHIKV, DENV and ZIKV. CHIKV has been 
Figure 2: Global map of the predicted distribution of Aedes aegypti. Map depicts probability of 




described to be primarily transmitted in the periods (i.e., -7 days to -3 days prior-to-delivery) and the 
intrapartum periods (i.e., -2 days prior-to-delivery to +2 days post-delivery), although congenital (i.e., 
>7 days prior-to-delivery) transmission has also been described66-69. Congenital and antepartum 
transmission of DENV have been reported with similar frequnency70-74. In contrast, ZIKV seems to be 
mainly transmitted congenitally, specifically via transplacental transmission, although some antepartum 
transmission has been documented65. 
1.6 Clinical presentation of CHIKV, DENV and ZIKV 
 The clinical presentations of CHIKV, DENV and ZIKV have been described to be very similar. 
However, frequencies of symptoms of the respective viruses are currently unspecified. Studies 
estimating the proportion of asymptomatic cases of CHIKV, DENV and ZIKV infections show a wide 
range of results. Hence, between 60% and 75% of DENV and ZIKV infections and 3% to 75% of CHIKV 
infections have been estimated to be asymptomatic75-78. Overall, there is significant overlap in the 
clinical symptoms of the three arboviruses, their incubation period, symptomatic period as well as the 
duration of the period when viral RNA persists in serum (Table 1)79. However, CHIKV and ZIKV 
infections have been described to not be characterised by bleeding, and DENV infections have only 
rarely been described to present with conjunctivitis79,80. Further, all three arboviruses are associated 
in rare cases with complications of infection, such as encephalopathy, encephalitis, myelitis, acute 
disseminated encephalomyelitis (ADEM) and GBS. A specific complication of CHIKV is a chronic stage 
characterized by unpredictable relapses, which include sensation of fever, muscular weakness, and 
worsening of joint stiffness as well as general viral polyarthropathy, which is defined as pain and 
inflammation in four or more joints. Most DENV complications occur due to a mechanism called 
antibody-dependent enhancement (ADE), which is enhanced disease severity due to a secondary 
infection caused by a different DENV serotype to the primary infection81. One specific DENV 
complication is Dengue haemorrhagic fever (DHF), which is characterized by plasma leakage of 
different severity levels. DHF can lead to Dengue shock syndrome (DSS), causing severe plasma 
leakage that can lead to shock in the patient. About 10% of all DENV cases have been reported to 




Table 1: Transmission and clinical presentation of CHIKV, DENV and ZIKV 
 CHIKV DENV ZIKV 
Transmission - Mosquito bitea83 
- Blood transfusion 
- Mother-to-child84 
- Mosquito bitea83 
- Blood transfusion 
- Mother-to-child85 
- Mosquito bitea 
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for progenitor neural cells in the developing human foetus, resulting in clusters of neurodevelopmental 
birth defects in approximately 5-10% of ZIKV infections in pregnancy86-93. Further, this neurotropism 
also causes a number of severe neurological complications in children and adults, which seem to be 
caused by both direct neuro-invasion (e.g., encephalitis) and post-infectious autoimmunity (e.g., GBS)1.  
1.7 Diagnostics 
  Diagnostic testing of CHIKV, DENV and ZIKV infections can be accomplished using both 
molecular and serological methods, but, as explained below, the choice of method depends on the 
number of days from infection or symptom onset (Figure 3)94. Thus, asymptomatic infections can make 
diagnostics challenging. 
 
 While viral RNA of CHIKV, DENV and ZIKV has been reported to persist for longer in some 
patients, viral clearance in the bloodstream during a typical infection occurs around 7 days after 
symptom onset (Table 1)76,79,95,96. Thus, molecular testing for viral RNA (e.g., quantitative real time 
Figure 3: Diagnostics of Chikungunya virus, Dengue virus and Zika virus. Time of molecular 
and serological testing during course of a primary infections of Chikungunya virus, Dengue virus and Zika 




polymerase chain reaction (qRT-PCR)) is predominantly conducted within the first 7 days of symptom 
onset (Figure 3)97. CHIKV, DENV and ZIKV RNA have also been detected in urine samples98,99.  In 
fact, the WHO even suggests PCR testing in urine samples for ZIKV RNA for up to 30 days97. 
Specifically for ZIKV, RNA can also be detected in semen for up to 60 days post symptom onset97. 
 Samples collected from patients after 7 days of symptom onset are subjected to molecular and 
primarily serological diagnostic testing97. Serological testing can include testing titres of Immunoglobin 
(Ig) M antibodies (i.e., from about 5 days to 12 weeks after symptom onset), IgG antibodies (i.e., from 
about 10 days to 6 months for ZIKV and CHIKV and for several years for DENV), which are both 
tested by antibody enzyme-linked immunosorbent assays (ELISA), or testing neutralizing antibodies 
using a plaque reduction neutralization test (PRNTs) (Figure 3) 97,100-102 103-105. However, there is a 
principal obstacle to ELISA serological testing: inherent serological cross-reactivity exhibited by the 
Flavivirus species, due to high frequency of common antibody epitopes106. Thus, depending on the 
validation cohort (e.g., cases from areas of high flavivirus co-circulation vs. travellers), IgM and IgG 
ZIKV ELISAs have been reported to indicate wide ranges of specificity (i.e., true negative rate) and 
sensitivity (i.e., true positive rate)102. In addition, in patients with previous DENV infection, the initial 
antibody response upon ZIKV infection has been described to be a DENV IgG response instead of a 
ZIKV IgM response, thus further reducing diagnostic sensitivity107. To validate ELISA results, the “gold 
standard” diagnostic for flaviviruses can be performed, which is the PRNTs103-105. Although this 
technique requires elaborate training and specialised facilities and is very labour-intensive and 
expensive, it is currently the only diagnostic tool to accurately differentiate viral infections. The 
evaluation of seroconversion is an additional diagnostic method of arbovirus infection. This is 
conducted by taking two consecutive samples and testing them by either IgM or PRNT108. 
Seroconversion by IgM can be confirmed, if there is a switch from negative status in the first sample 
to positive status in the second sample108. Seroconversion by PRNT can be confirmed by a rise in 
PRNT titers between the two samples or a switch from negative status in the first sample to positive 




1.8 Treatment and vaccines 
 To date, there is no licenced antiviral therapeutic for CHIKV, DENV or ZIKV infections. 
Treatment of symptoms is the only clinical resource to manage CHIKV, DENV and ZIKV infected 
patients. These treatments include rest, hydration and specific pain medication. DENV infected patients 
should only receive acetaminophen (i.e., paracetamol), and should strictly avoid aspirin and ibuprofen, 
as these nonsteroidal anti-inflammatory drugs (NSAIDs) can cause a mild DENV clinical presentation 
to develop into a severe DENV clinical presentation, which may require hospitalisation and sometimes 
even intensive care treatment109. After a DENV infection has been ruled out, CHIKV and ZIKV patients 
can be treated with NSAIDs in addition to acetaminophen110-112.      
 In contrast to DENV, there are no approved CHIKV and ZIKV vaccines to date, although a 
number of CHIKV and ZIKV vaccines are currently under trial113-118. For DENV, a live attenuated 
vaccine, chimeric yellow fever 17D-tetravalent dengue vaccine (CYD-TDV) has been licensed by the 
U.S. Food and Drug Administration119. However, in 2017 the vaccine manufacturer, Sanofi Pasteur, 
announced that people who receive the CYD-TDV vaccine without previously having been DENV 
infected may be at risk of developing severe DENV fever if they become DENV infected after being 
vaccinated120. These adverse vaccine outcomes led to the vaccine being exclusively administered to an 
age group of 9 to 45 years with documented confirmed previous DENV infection. Nevertheless, those 
most at need of DENV vaccines are the paediatric cases (i.e., 1 to 15 years of age) in endemic DENV 
regions, as DENV fever and DHF mainly affect children under 15 years of age121. Thus, the licensed 
vaccine is of limited use. As such, the seven DENV vaccine candidates currently in trial, including an 
additional two live attenuated vaccines, an inactivated virus vaccine, a recombinant subunit vaccine, a 
viral vectored vaccine, and two DNA vaccines are of great importance122.   
1.9 Co-infection of arboviruses 
The circulation of arboviruses in tropical and subtropical areas, where the prevalence of other 
infectious pathogens is high, leads to an increased risk of co-infection with co-circulating arboviruses 
and other infectious diseases123. Co-infected patients can present with similar clinical manifestations 




missed diagnosis of one or more of the multiple infecting agents restricts epidemiological 
understanding of co-infection, which has serious potential implications for the health outcomes of 
infected patients. For example, misdiagnosing a DENV as a CHIKV infection or missing a DENV co-
infection may lead to inappropriate prescription of arthralgia alleviating NSAIDs. These are usually 
used for CHIKV patients, but, as previously described, lead to severe bleeding in DENV patients with 
thrombocytopenia or DHF125. A systematic review on CHIKV/DENV co-infections describes the 
clinical presentation of co-infections in four studies. However these studies were of limited 
methodological quality126. Three of those studies, a case report and two cross-sectional studies, found 
neither symptoms nor clinical outcomes of co-infections (n=85 cases) were exacerbated in relation to 
mono-infections126-129. The fourth, a hospital-based case series by Chahar and colleagues found a high 
rate of severe symptoms and poor clinical outcomes among co-infected patients (n=6 cases), but no 
details were provided regarding the clinical presentation of DENV or CHIKV mono-infected patients, 
to allow comparison130.    
Moreover, the extent to which co-infection could enhance disease severity remains unclear. 
Vogels and colleagues recently hypothesized various scenarios of how co-infections could act on 
arboviral replication and associated pathology131.  
 
 
Figure 4: Possible scenarios of impact of co-infection on arbovirus replication and 





These scenarios are depicted in Figure 4 and include: 
• Enhancement of viral replication and following pathology. 
• Inhibition of viral replication and following pathology. 
• Competition between the virus and the co-infecting agent, resulting in viral 
replication and pathology identical to mono-infection of the “winning” agent. 
• Neutral relationship between virus and co-infecting agent, no effect on viral 
replication or pathology. 
Enhancement of pathology could either occur through an increased viral replication due to 
simultaneous interaction with the immune system by multiple pathogens, or an exacerbated immune 
response to an increased viremia131. Vogels and colleagues describe possible enhanced virus replication 
through a CHIKV/DENV co-infection inhibiting two fundamental antiviral responses simultaneously 
(e.g., CHIKV interferes with the nuclear transport of signal transducer and activator of transcription 
1 (STAT1) and DENV blocks STAT2 phosphorylation132. STAT1 and STAT2 are two transcription 
factors involved in interferon signalling). Additionally, a cellular exonuclease that degrades viral RNA, 
5′-3′ exoribonuclease 1 (XRN1), may promote replication of flaviviruses, such as ZIKV and DENV, 
when co-infecting the same cell133.  Finally, endothelial permeability during DENV infection may change 
tissue tropism of co-infecting viruses to enhance viral pathology134.    
 An alternative potential consequence of co-infection could be the triggering of an increased 
immune response, which would lead to reduced overall viremia and consequently to reduced disease 
severity, resulting in overall inhibition of pathology131. Two co-infecting pathogens could likewise be 
competing to infect the same cells, which would result in identical clinical presentation as monotypic 
infection of the “winning” virus104. This has been described for a CHIKV/DENV co-infected patient, 
where the DENV replication was reported to be suppressed131,135. Finally, co-infecting pathogens could 
also have no impact on each other’s replication or clinical presentation, as has been reported in 
CHIKV/DENV co-infections126,129.        
 The number of reported co-infections with CHIKV, DENV and ZIKV is low. Furthermore, the 




the prevalence of short- and/or long-term clinical presentation potentially caused by co-infection. In 
addition, the frequency of co-infections of CHIKV, DENV and ZIKV with co-circulating arboviruses or 
other infectious pathogens remains uninvestigated, largely because evaluating the co-infection 
frequency is challenging due to the dynamic background of mono-infection frequencies (i.e., the 
denominator for assessing co-infection frequency). This challenge of assessing mono-infection 
frequencies arises from the diagnostic difficulties in identifying acute CHIKV, DENV and ZIKV 
infections108,126. Finally, the impact of co-infection on a developing foetus in pregnancy remains 
unknown. 
1.10 Arboviruses in pregnancy: CHIKV, DENV and ZIKV 
 Arboviruses infections in pregnancy expose pregnant women to various risks. Such risks can 
include more severe infection in pregnant women than in the general adult population, as during 
pregnancy several pathophysiological changes and immune adaptations occur to accommodate the 
foetus136. Thus, in pregnant women an arbovirus infection may lead to a more severe clinical 
presentation or even death85. Additionally, there is a risk of pregnant women transmitting the 
arbovirus to their foetus (i.e., antepartum mother-to-child transmission), which could lead to a risk of 
miscarriage (i.e., foetal loss before 28 weeks of gestation), stillbirth (i.e., foetal loss at 28 weeks of 
gestation or later), intrauterine growth restriction (IUGR) and/or a teratogenic effect on the foetus. 
Furthermore, women infected during late pregnancy risk transmitting the arbovirus close to birth or 
during delivery of the foetus (i.e., peripartum/ intrapartum mother-to-child transmission), which could 
result in severe neonatal infection. To date, limited data are available for CHIKV, DENV, and ZIKV 
infections in pregnancy, and each virus seems to impact the health of mother and foetus when infected 
in pregnancy differently (Table 2). 
 CHIKV antepartum (i.e., >7 days prior-to-delivery) and peripartum (i.e., 7 days to 3 days prior-
to-delivery) mother-to-child transmission (MTCT) have been described84. A systematic review 
including a meta-analysis by Contopoulos-Ioannidis and colleagues found that the overall pooled risk 
of MTCT of 1331 CHIKV infections was 12.6% (95%CI: 13.6%-17.5%) and among 46 intrapartum 




34.9%-65.1%)84. Additionally, the review found no increased risk of miscarriages associated with 
CHIKV infections and no increase in the number of stillbirths, prematurity, or congenital 
malformations84. Nevertheless, the overall pooled-risk from 8 studies of symptomatic neonatal disease 
among maternal CHIKV infected women during gestation was 11.9% (95%CI: 3.9%-19.9%) and among 
intrapartum maternal infection from 3 studies was 50.3% (95%C: 3.8%-96.9%)66,137. Symptomatic 
infected newborns from maternal infections during gestation usually developed symptoms during their 
first week of life, but not at the time of birth. Commonly reported signs and symptoms included fever, 
diffuse limb edema, irritability, poor feeding, painful syndrome and rashes; occasionally, additional 
symptoms include sepsis-like syndrome with multiple organ involvement, meningoencephalitis with 
brain MRI abnormalities and sometimes even long term neurodevelopmental delays and devastating 
neurologic outcomes such as cerebral palsy84.  
In contrast to CHIKV, DENV has been described to cause an increased risk of severe disease 
in pregnant women in comparison to non-pregnant women, leading to DHF and DSS (OR 3.4, 95%CI: 
2.1-5.4)70,138,139. Mortality among pregnant women with DHF increased relative to non-pregnant 
women with DHF (maternal mortality ratio in the DENV exposed cohort was about 1020 per100 000 
live births)85,140. Further, antepartum mother-to-child transmission of DENV has been documented 
and is associated with increased foetal loss in the first half of pregnancy70-72. A recent retrospective 
study using linkage data was conducted on more than 16 million live births exposed to DENV in 
pregnancy from Brazil from 2006-2012141. The study suggests that DENV infection during pregnancy 
increases the odds of developing neurologic congenital anomalies by 50% and leads to a 4-fold increase 
for other congenital malformations of the brain, providing new evidence of an association of antenatal 
DENV infection in pregnancy with congenital anomalies of the brain141. Additionally, consequences of 
peripartum DENV mother-to-child transmission have been reported to cause severe neonatal 
infection with sepsis-like symptoms and acute respiratory distress73,74.   
 Antepartum ZIKV mother-to-child transmission has been reported to be associated with 




       
Table 2: CHIKV, DENV and ZIKV in pregnancy. Adapted from Charlier et al. (2017)10. 
 CHIKV DENV ZIKV 





Risk of severe infection,     
+  
risk of DHF/DSS 85 
= 
Consequences of antepartum mother-to-child transmission 
Transmission Documented, low 
incidence84 
Documented72 Documented142 
Miscarriagee = 84 +72 (+)86 
Stillbirthb  = 143  (+)144 (+)86 
Preterm birth  = 143 +72 Documented86 
Low birthweight  = 143 +72 n/a 
Malformations               =  +141                         
Malformation of spinal 
cord (OR 5.4, 95% CI 
1.0–26.9), 
Microcephaly                        
(OR 1.7, 95% CI 0.33–
8.32),                              
      +145,146                 
Teratogenic, incidence 
of brain abnormalities 
in 1-13%, Severe 
microcephaly and 








      +147-149 
Impaired neurological 






Consequences of peripartum mother-to-child transmission 
Transmission 
Documented84,               
peripartum 
transmission rate 50%                              
(95%CI: 34.90%-
65.10%; 23/46) 
Documented74,                
Incidence unknown 
Documented150,                    
rare 
Consequences 
+84,151                                  
Neonatal symptomatic 






+73,74                           
Severe neonatal 
infection with sepsis-
like symptoms and 
acute respiratory 
distress reported in 
case reports 
 
=150                                   
One asymptomatic 
and one case with 
mild rash (case 
reports from French 
Polynesia) 
Neonatal death 
2.8% (95% CIs: 0.90%-
6.29%; 5/182)84 
n/a n/a 
+ increased, (+) possibly increased, = not increased, n/a no data available, aMiscarriages are foetal losses 
before 28 weeks of gestation. bStillbirths are foetal losses at 28 weeks of gestation or later. cAt ~2 years of 






developmental defects and teratogenicity142. The highest risk period of maternal ZIKV infection for 
damage to the central nervous system (CNS) has been proposed to be the first trimester or at the 
start of the second trimester, while impact on foetal growth and development may continue to occur 
with maternal infection well into the third trimester145,146,152. Congenital Zika Syndrome (CZS) has 
been described by the United States Centers for Disease Control and Prevention (CDC) as having 
five unique features that can be used to differentially diagnose CZS from other congenital conditions. 
These are: i) severe microcephaly in which the skull has partially collapsed; ii) decreased brain tissue 
with a specific pattern of brain damage, including subcortical calcifications; iii) damage to the back of 
the eye, including macular scarring and focal pigmentary retinal mottling; iv) congenital contractures, 
such as clubfoot or arthrogryposis; and v) hypertonia restricting body movement soon after birth153. 
Moreover, impaired postnatal neurological development with poor cranial growth, irritability, 
pyramidal or extrapyramidal symptoms, as well as dysphagia and epilepsy have been reported147-149. 
Peripartum mother-to-child transmission of ZIKV has been rarely reported and seems to mainly cause 
























1.11 Study justification 
CHIKV, DENV and ZIKV are the arboviruses of current public health concern in Latin America6. 
This public health relevance is manifested by their growing prevalence and ongoing co-circulation over 
the past 20 years in Latin America, and the continuing lack of optimal tools for prevention (e.g., 
vaccines) and treatment of infections (e.g., antivirals). CHIKV, DENV and ZIKV cause similar clinical 
symptoms, which make diagnosis and subsequent disease supportive care and prognosis a difficult 
challenge. This difficulty has potential implications for the health outcomes of patients and pregnancy. 
The co-circulation of arboviruses in tropical and subtropical areas has led to the likelihood of 
co-infection occurring with arboviruses and other infectious diseases prevalent in these areas.           
Co-infected patients can present with similar clinical manifestations to monotypic infected patients, 
which complicates differential diagnosis129,154,155. Additionally, the actual influence of co-infections on 
the clinical presentation of respective arbovirus infections remains unstudied. Therefore, the frequency 
of co-infection occurrences and their impact on the clinical presentation of arboviruses should be 
assessed. In my research I chose to focus on concurrent co-infections of ZIKV infections. This is 
because a different systematic review identified no clinical significance on either symptoms or clinical 
outcomes of DENV/CHIKV co-infection. Moreover, ZIKV caused the largest arbovirus outbreak from 
2015-2017 in Latin America, and in contrast to DENV and CHIKV infections, the short period of global 
ZIKV research has not yet evaluated the clinical significance of ZIKV co-infection. 
 An additional key concern regarding the setting of arbovirus co-circulation is the accurate 
identification of the specific arbovirus infections and co-infections. This is a particular challenge as the 
mild clinical presentation of CHIKV, DENV and ZIKV has been described to be similar156. All three 
arboviruses present with rash, fever, myalgia, arthralgia, conjunctivitis and headache. However, to date 
frequencies of signs and symptoms are unspecified59,157. As molecular testing was unavailable for DENV 
infections (i.e. PCR testing for the detection of DENV virus), serology of DENV infections was 
explored, but due to the high observed cross-reactivity between the flaviviruses DENV and ZIKV in 
serological testing (e.g. for the CDC MAC-ELISA for DENV IgM)106, DENV infections have been 




frequencies of clinical signs and symptoms have been described in isolation from each other15,50,86,158-
160.  Furthermore, to our knowledge only three studies have reported the clinical presentation of 
CHIKV infections alongside ZIKV infections. However, these studies suffer from limitations of quality 
data and lack of explanation of statistical and diagnostic methods used161-163.   
 Nevertheless, an accurate differential diagnosis of ZIKV and CHIKV infections is fundamentally 
important, as complications differ strongly between them. In adults and children, ZIKV infection has 
mainly been associated with the development of neurological complications, such as GBS, while CHIKV 
infection has been associated with neurological complications as well as persistent, disabling severe 
arthralgia59,157,164. Regarding mother-to-child transmission, not only have maternal ZIKV infections 
during pregnancy been confirmed to cause adverse birth outcomes, such as microcephaly, but maternal 
CHIKV infection around birth have also been reported to lead to severe long-term 
neurodevelopmental delays60. These known complications and long-term sequelae of ZIKV and CHIKV 
infections are becoming increasingly recognized and can lead to severe morbidity.   
 The co-circulation of CHIKV and ZIKV requires research. Hence, I chose to characterize the 
co-circulation of CHIKV and ZIKV within a cohort of pregnant women that presented with rash from 
2015 to 2017 in Recife, Pernambuco, Brazil and investigate whether the symptom frequencies of the 
clinical presentation between ZIKV and CHIKV infections differ from each other108. To note, evidence 
displays that the clinical presentation of ZIKV and CHIKV infections are very similar in the general 
population and in pregnant women50,136,165-170. Additionally, the study of pregnant women in this 
context is highly relevant as they represent a sub-group especially at risk of serious complications.  
 To summarize, this study was conducted under the hypothesis that the differentiation of the 
respective arbovirus infections at the stage of symptom presentation could potentially facilitate clinical 
diagnosis. As CHIKV, DENV and ZIKV predominantly circulate in low-income settings and arbovirus 
laboratory testing is costly and time consuming, differentiating arbovirus infections upon symptom 
presentation would not only enable health care workers without access to laboratory testing to 
diagnose the origin of infection, it would also help them to diagnose the respective infection early after 




of an early initiation of appropriate clinical management and required follow up, which would reduce 
arbovirus infection associated complications and also remove potential strain from the health system. 
In addition, diagnosing an arbovirus infection upon symptom presentation will also guide laboratory 
testing by narrowing down the pathogens to be tested for, which is also of high relevance if resources 
for testing are limited. Furthermore, the consequences of early diagnosis, reducing testing, timely 
intervention and thus lowering numbers of arbovirus infection associated complications would relieve 
the public health services both financially and capacity-wise. 
 Taken together, my systematic review and my descriptive study of this MPhil research project 
aim to contribute to what is known on co-circulating arboviruses in Latin America by contributing to 
fill the gap of knowledge on clinical significance of ZIKV co-infections and evaluating the clinical 
presentation of CHIKV and ZIKV infections. Overall, this study aims to improve preparedness for 
future arbovirus outbreaks in a time of ongoing arbovirus co-circulation and continuing unavailability 
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2. CHAPTER II:  METHODS & RESULTS 
 This chapter contains two research papers that form the basis of my study. The first paper 
systematically reviews ZIKV co-infections, including assessing the co-infection frequency among ZIKV 
infected cases and the impact of co-infections on the clinical presentation of ZIKV infections             
(Paper 1). The second paper demonstrates the temporal and geographical co-circulation of CHIKV 
and ZIKV in a cohort of pregnant women presenting with rash in Recife, Brazil from 2015 to 2017. 
Furthermore, the second paper also investigates whether CHIKV and ZIKV can be differentiated upon 
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Vierira de Souza, Demócrito de Barros Miranda-Filho, Ricardo Arraes de Alencar Ximenes, Luciana 
Caroline Albuquerque, Rafael Dhalia, Ernesto Torres Azevedo Marques-Junior, Elizabeth B Brickley  
Author contribution:  
LL developed the research question. LL completed the data analysis under the supervision of EW. LL 
created the figures and wrote the first draft manuscript. Other authors are currently reviewing and 
providing feedback on the manuscript prior to submission. 
 
Word count : (4320/4500) 
Keywords: Zika, Chikungunya, Arbovirus, Co-circulation, Clinical presentation 
Figure / Tables: 2 Figures, 4 Tables 
















 Increased co-circulation of arthropod-borne viruses (arboviruses) has been reported in Latin 
America and the Caribbean, two of which are Zika virus (ZIKV) and Chikungunya virus (CHIKV). To 
date, differential diagnosis of these two arboviruses remains complicated, due to their reported 
overlapping clinical presentations. Our study aimed to describe the co-circulation of ZIKV and CHIKV 
within a cohort of pregnant women during the outbreak and decline of the ZIKV from 2015 to 2017 
in Recife, Pernambuco, Brazil. In addition, we investigated whether the clinical presentations of ZIKV 
and CHIKV infected cases may be differentiatable. Geographic and temporal CHIKV-ZIKV co-
circulation was demonstrated by our findings, based on 213 ZIKV mono-infections, 55 CHIKV mono-
infections and 58 sequential ZIKV/CHIKV infections within the cohort. Furthermore, we found that 
among CHIKV mono-infected cases, certain symptoms, specifically joint pain, joint swelling, fatigue and 
headache, were more frequently reported than among ZIKV mono-infected cases. Our findings could 
help healthcare workers to differentiate between CHIKV and ZIKV infections in the event of CHIKV-
ZIKV co-circulation in a ZIKV outbreak, in order to guide diagnostic testing and implementation of 















Arthropod-borne viruses (arboviruses) are a growing threat to public health, increasingly 
contributing to global disability and mortality. 1-3 Simultaneously, an advancing geographic and temporal 
co-circulation of arboviruses has been reported worldwide, driven by a combination of factors 
including urbanization, increased population movement and climate change. 4-6 Growing deforestation 
and urbanization has led to increased vector-host interaction, while enhanced population movement 
and changing climate facilitate the spread of viruses (e.g., in infected humans) and vectors (e.g., in 
containers and ships) to previously unaffected locations. 7,8 Poor sanitation conditions, such as water 
storage due to limited supply and inadequate sewage disposal, also generate conditions suitable for 
mosquito proliferation and this is intensified by rising insecticide resistance of mosquitoes. 8,9 In Latin 
America especially, the co-circulating arboviruses Chikungunya virus (CHIKV), Dengue virus (DENV) 
and Zika virus (ZIKV) are of increasing public health concern. 10 The three viruses are mainly 
transmitted by the same vector, Aedes aegypti, an urban and peri-urban mosquito, which is present in 
almost all tropical and subtropical areas. 3,11 Currently over 3 billion people live in regions where Aedes 
aegypti is present and as a result are at risk of arboviral infection. 11 
A major concern regarding the co-circulation of ZIKV, DENV and CHIKV is the accurate 
discrimination between arboviral infections, as the mild clinical presentation of the three arbovirus has 
been reported to strongly overlap. 12 To note, CHIKV, DENV and ZIKV infections can be 
asymptomatic, however whereas DENV and ZIKV infections are thought to be asymptomatic in 60-
75% of infections, CHIKV has been described to be asymptomatic in 3-75% cases. 13-16 All three 
arboviruses present with rash, fever, myalgia, arthralgia, conjunctivitis and headache, however with to 
date unspecified prevalence of signs and symptoms. 17-19 Additionally, laboratory diagnosis can be 
challenging, especially in distinguishing between the flaviviruses DENV and ZIKV, for which high cross-
reactivity of serological testing has been reported. 20 An accurate differential diagnosis is fundamentally 
important, as complications differ strongly between ZIKV, DENV and CHIKV infections. ZIKV 
infection has mainly been associated with the development of neurological complications, such as 
Guillain-Barré syndrome and adverse birth outcomes such as microcephaly. 19 DENV infection may 
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lead to the development of dengue haemorrhagic fever, which can lead to dengue shock syndrome, 
sometimes resulting in death, while CHIKV infections have been associated with neurological 
complications as well as persistent, disabling severe arthralgia. 17,18 As known complications and long-
term sequelae of these infections are becoming increasingly recognized and can lead to severe 
morbidity, the co-circulation of CHIKV and ZIKV warrants focused investigation.   
This study aimed to characterize the geographical and temporal co-circulation of CHIKV and 
ZIKV within a cohort of pregnant women that presented with rash during the outbreak and decline 
of the ZIKV from 2015 to 2017 in Recife, Pernambuco, Brazil. 21 Due to the inherent obstacle of 
serological flavivirus cross-reactivity, DENV infections could not be included in our analyses. In 
addition, this study investigated whether there were differences in the clinical presentation between 
ZIKV mono- and CHIKV mono-infections, and between ZIKV-mono-infections and sequentially 
ZIKV/CHIKV infections in pregnant women, in order to potentially facilitate clinical diagnosis and guide 


















The study was approved by the ethics committee of Fiocruz, Pernambuco, Brazil (Comitê de 
Ética em Pesquisa do Instituto Aggeu Magalhães (CEP/ CPqAM/Fiocruz)) (1.533.226) and by the ethics 
committee of the London School of Hygiene and Tropical Medicine (LSHTM Ethics Ref:16412). 
Study design 
This was a cross-sectional study, nested within a cohort, which was conducted by the 
Microcephaly Epidemic Research Group (MERG). 21 The study’s population was a cohort of  pregnant 
women who presented with rash (n=694) during the decline of ZIKV in Recife, Pernambuco, Brazil 
between December 2015 and June 2017. All 694 pregnant within the cohort study were seen at a 
maximum of three study visits, with some visits taking place after delivery. 21 All 694 pregnant women 
completed an extensive questionnaire, and blood samples were collected. 21 Detailed information on 
the design of the cohort study, participants and laboratory procedures has been previously described 
by Ximenes and colleagues (2019). 21 The median total income per month of people living in the house 
of a pregnant woman was presented in relation to the Brazilian minimum wage in 2016 (i.e., relative 
to minimum wage in 2016 880 BRL/Month, the equivalent of about 172 US$/month). 22 
Laboratory testing 
 The  diagnostic testing of the blood samples was conducted at the Laboratorio de Virologia e 
Terapia Experimental of the Fundação Oswaldo Cruz (LAVITE-FIOCRUZ, Recife, Pernambuco). 21 
Blood samples were tested for ZIKV, by Quantitative Reverse Transcription Polymerase Chain 
Reaction (qRT-PCR) and with primers described by Lanciotti and colleagues, 23 by capture-IgM 
enzyme-linked immunosorbent assay (ELISA) as described by the United States Centers for Disease 
Control (CDC, Fort Collins, Colorado, United States of America), 24 and by Plaque Reduction 
Neutralization Test (PRNT50). 21 Additionally, blood samples were tested for CHIKV and DENV by 
IgM-ELISA (CDC MAC-ELISA). Testing regimes varied across the cohort, as not all ZIKV tests were 
available or appropriate for blood samples, depending on when the sample was taken. For example 
qRT-PCR could only be used near the time of acute rash, when viral RNA was still detectable in the 
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blood sample, and ELISA IgM could only be used approximately 3 days to 2 month after infection, 
when IgM antibodies have developed in the blood stream. 25 For each woman, a panel of experts, 
consisting of three virologists, one infectious disease specialist, and one epidemiologist, reviewed all 
their lab results over time in relation to the dates of rash onset and pregnancy and developed a 
diagnostic algorithm that defined each individual ZIKV infection in pregnancy. 21 The development of 
the diagnostic algorithm for ZIKV infection was done blinded to data on later pregnancy outcomes. 21 
Recent CHIKV infections and recent DENV infections were identified through IgM.  
 Due to reported cross-reactivity of DENV IgM tests with acute ZIKV infected serum, true 
DENV infections could not be differentiated from false positive recent DENV infection results. 20 
Therefore, this analysis focused on ZIKV and CHIKV infected pregnant women within the cohort, 
where flavivirus cross-reactivity does not apply, as CHIKV is an alphavirus. 18 Thus, all pregnant women 
testing positive for DENV IgM were excluded from the statistical analysis comparing the clinical 
presentation of ZIKV and CHIKV infections or ZIKV and sequential ZIKV/CHIKV infections. In the 
cohort we defined "sequential ZIKV/CHIKV infection" as a pregnant woman, with a confirmed ZIKV 
infection, as described above, and a simultaneaous postive CHIKV IgM test results, confirming recent 
CHIKV infection (i.e., within 3 to 4 days and up to 2 months after ZIKV infection, defined by the 
WHO). 26  As infections of TORCH agents (i.e., TORCH - Toxoplasma gondii, others (e.g., parvovirus 
and HIV), rubella virus, cytomegalovirus, herpes simplex virus) in pregnancy are most commonly 
associated with miscarriage, stillbirth, intrauterine growth restrictions, foetal developmental defects 
and teratogenicity, the pregnant women were additionally tested for recent infections of TORCH 
pathogens by ELISA IgM. 27 
Temporal and geographical investigation of ZIKV and CHIKV co-circulation 
For the investigation of the temporal co-circulation of CHIKV and ZIKV within the pregnant 
women cohort an epidemiological curve was generated, which depicts pregnant women that tested 
positive for ZIKV, CHIKV and the total number of pregnant women with rash that were notified 
within the cohort by epidemiological week (EW) and epidemiological month (EM) over the time period 
from December 2015 to June 2017. In addition, the effect of seasonality on the number of infections 
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was assessed graphically, by indicating the epidemiological months of the rainy season in Recife, 
Pernambuco, Brazil within the graph. 28  
A map was created to visualize the geographical co-circulation of CHIKV and ZIKV within the 
pregnant women cohort. ArcGIS software (ArcGIS, release 10.5. Redlands, CA: Environmental 
Systems Research Institute) was used to geo-reference the residence of the pregnant women, 
providing geographical coordinates (latitude and longitude). The Brazilian Institute of Geography and 
Statistics (IBGE) website (https://mapas.ibge.gov.br/bases-e-referenciais/bases-cartograficas/malhas-
digitais.html) provided a cartographic basis for the city of Recife in the shapefile format in the 
“geographic” projection system (latitude and longitude) and SIRGAS 2000, which was updated in 2010. 
29,30 Using ArcGIS, the residential location of each pregnant woman with positive ZIKV test results 
was first plotted over a layer of the city map of Recife, on which a layer of pregnant women with 
positive CHIKV test results was then plotted on top. The map was made at a scale of 1:100,000, which 
produces an error of approximately 20 m on the real scale (0.2 mm on the map). Therefore, the 
residence of each pregnant woman is represented as a broad circle of approximately 1250 m2 within 
a highly urbanized city. The map does not reveal the precise residential location of the pregnant 
women, therefore ethical concerns regarding identification do not apply.      
Statistical analysis to compare the clinical presentation of ZIKV and CHIKV infections 
 In order to assess if there is a difference in the prevalence of signs and symptom between 
ZIKV and CHIKV mono-infections, first the prevalence of respective signs and symptoms for ZIKV 
mono- and CHIKV mono-infections was calculated and summarized with the 95% confidence intervals 
(CI). Crude associations between symptom prevalence of CHIKV and ZIKV mono-infections were 
assessed using logistic regression  (e.g., mathematical formulation to calculate the crude odds ratios of 
presenting with joint pain when CHIKV infected vs ZIKV infected: logit jointpain i.chikv/zikv), resulting 
in odds ratios for presenting with a sign or symptom when CHIKV mono-infected vs. ZIKV mono-
infected, which were reported with 95% CIs and a p-value from a likelihood ratio test in the logistic 
model . Logistic regression was also used to adjust for the potential confounder of maternal age, 
resulting in adjusted odds ratios (e.g., mathematical formulation to calculate odds ratio for presenting 
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with joint pain when CHIKV infected vs ZIKV infected, adjusted for maternal age: logit jointpain 
i.chikv/zikv i.maternalage),which were presented with 95% CIs and a p-value from a likelihood ratio 
test in the logistic model. All statistical analyses described above were also conducted comparing ZIKV 
mono-infections with sequentially ZIKV/ CHIKV infections. 
Finally, predictive modelling was conducted, using logistic regression, to see whether a 
combination of signs and symptoms is more predictive of being CHIKV mono-infected vs. ZIKV mono-
infected than each sign and symptom in isolation, for which odds ratios were presented with a 95% CI 























 The study cohort included 694 pregnant women, of which the majority (79%), resided in the 
Recife metropolitan area (Table 1). The median age of the women was 25.5 years (IQR: 21, 31). The 
women self-identified with various ethnicities, the most common ethnicity was “pardo” (i.e., mixed 
race) (65%), followed by “branco” (i.e., white) (23%), followed by “preto” (i.e., black), (10%) and the 
least frequent ethnicity was Asian (2%). Median schooling years of the women was 10 years (IQR: 8, 
11) and median total income per month of people living in the house of a pregnant woman was 1.3 
(IQR: 1.0, 2.2) times the Brazilian minimum wage in 2016. Overall, comorbidities during pregnancy 
were low, apart from gestational hypertension in 20% (n=131) of women and anaemia in 29% (n=179) 
of women. However, this proportion of anaemia among pregnant women has been reported to be 
usual for Brazil. 31  Although 10% of women had evidence of recent Herpes simplex virus (HSV) 
infection (10% were IgM positive), only 2% overall had positive recent serological test results for 
TORCH agents, including 2% of women were parvovirus IgM, 1% toxoplasmosis IgM and 0.2% 
cytomegalovirus IgM positive.  
Arbovirus laboratory test results 
 The laboratory diagnostic results showed that of the 694 women included in the study, 305 
(44%) had evidence of an acute ZIKV infection and 145 (21%) had evidence of a recent CHIKV infection 
(Table 2). 26 The analysis of the temporal and geographical distribution of ZIKV and CHIKV infections 
was based on data from all 694 pregnant women. 
  For the analyses of clinical signs and symptoms of ZIKV and CHIKV infections a total of 66 
women with DENV IgM positive test results (34 with ZIKV and 32 with CHIKV infections) were 
excluded, due to reported cross-reactivity of DENV IgM ELISAs with acute ZIKV serum. This left a 
total of 213 (31%) pregnant women with ZIKV mono-infections, 55 (8%) with CHIKV mono-infections 




Temporal and geographical investigation of ZIKV and CHIKV co-circulation 
 The epidemiological curve shows simultaneous laboratory confirmation of CHIKV and ZIKV 
infections within the pregnant women cohort in Recife per week between December 2015 and June 
2017 (Figure 1). The majority of CHIKV and ZIKV infections occurred between December 2015 and 
May 2016, with a peak of up to 30 ZIKV infected pregnant women and up to 15 CHIKV infected 
pregnant women per week. An increase of CHIKV and ZIKV infection notification suggest a strong 
rise in cases between December 2015 and May 2016 (Figure 1). From June 2016 to August 2016 
numbers of CHIKV and ZIKV infections decreased to less than five pregnant women testing positive 
per week, followed by no new occurring infections between September and November 2016 and 
isolated CHIKV and ZIKV infections reappearing in pregnant women between December 2016 and 
June 2017. To note, the rainy season in Recife takes place between the months of March and August 
each year. 28 The mapping of pregnant women with CHIKV and ZIKV infections on the city of Recife, 
revealed that pregnant women with CHIKV, ZIKV and sequential ZIKV/CHIKV infections lived in 
strongly overlapping areas of the city, however without any recognizable pattern differentiating the 
occurence of CHIKV and ZIKV infections (Figure 2).  
Clinical presentation of ZIKV and CHIKV-infections 
 In this cohort, CHIKV mono-infected pregnant women more frequently presented with 
symptoms compared to ZIKV mono-infected pregnant women within the cohort study (Table 3). This 
relationship was observed for nearly all symptoms (i.e., joint pain, headache, muscle pain, back ache, 
fatigue, joint swelling nausea, photophobia, retro-orbital pain and abdominal pain), apart from fever 
and eye redness which occurred with similar frequency in both groups. In particular, joint pain, joint 
swelling, fatigue and headache were more common among CHIKV mono-infected pregnant women 
compared to ZIKV mono-infected pregnant women with an adjusted OR of 2 or more (joint pain: 
adjusted OR=2.98 (95%CI 1.61-5.28); joint swelling: OR=2.87 (95%CI 1.45-5.65); fatigue OR=2.46 
(95%CI 1.26-4.78); headache OR=2.25 (95%CI 1.20-4.20)).    
 Sequentially ZIKV/CHKV infected pregnant women also presentation more frequently with 
symptoms compared to ZIKV mono-infected pregnant women within the cohort study (Table 4). 
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Approximately half of the observed signs and symptoms were more common in sequential 
ZIKV/CHIKV infected pregnant women than in ZIKV mono-infected pregnant women (i.e., joint pain, 
headache, muscle pain, back ache, fatigue, and nausea), whereas fever, joint swelling, photophobia, 
retro-orbital pain, abdominal pain and red eyes were present in similar proportions of pregnant 
women in both groups. In particular, fatigue, nausea, and joint pain were more common among 
sequentially ZIKV/CHKV infected pregnant women compared to ZIKV mono-infected pregnant 
women with an adjusted OR of around 2 or more (fatigue: adjusted OR=2.63 (95%CI 1.38-5.03); 
nausea: OR=2.54 (95%CI 1.21-5.35); joint pain: OR=1.85 (95%CI 1.01-3.38)).  
 Predictive modelling of which combination of signs and symptoms would be more indicative 
for CHIKV mono-infection compared to ZIKV mono-infection, found that when symptoms were 
combined within the model there was no improvement in model fit, compared to when individual signs 
and symptoms were included alone in the model, and thus no combinations could be identified to be 
more indicative for one infection type (Supplementary Table 1). Further investigation revealed that 
















 Our study demonstrates geographical and temporal co-circulation of CHIKV and ZIKV within 
a cohort of pregnant women during the outbreak and decline of the ZIKV between 2015 and 2017 in 
Recife, Pernambuco, Brazil. In the cohort of pregnant women, those with CHIKV mono-infections 
presented more frequently with symptoms compared to those with ZIKV mono-infections, with 
differences most apparent for joint pain, joint swelling, fatigue, retro-orbital pain and headache. 
Additionally, pregnant women with sequential ZIKV/CHIKV infections presented more frequently with 
symptoms compared to pregnant women with ZIKV mono-infections, significantly for symptoms such 
as fatigue, nausea, and joint pain. As CHIKV-ZIKV co-circulation is increasingly being reported, our 
findings are relevant to facilitate clinical diagnosis and to guide laboratory testing. This is needed to 
ensure appropriate follow up to prevent and prepare for potential complications associated with 
CHIKV and ZIKV infection, such as persistant arthralgia, Guillain-Barré syndrome and adverse birth 
outcomes. Particularly, this study of pregnant women, including their correct clinical diagnosis is highly 
relevant, as they represent a sub-group particularly at risk of serious complications, especially in the 
case of ZIKV infection during pregnancy potentially leading to the development of congenital Zika 
syndrome within the fetus.  
Since 2015, when ZIKV was first discovered in Brazil, temporal and geographical CHIKV-ZIKV 
co-circulation has been frequently described throughout Latin America and the Caribbean (LAC)32-34. 
CHIKV emerged in LAC in 2013, following introduction from Asia to the Caribbean island of Saint-
Marteen. 35 By the beginning of 2014 CHIKV had arrived on the LAC mainland and quickly spread 
throughout the continent. 35 ZIKV meanwhile, was first identified on the LAC mainland in the 
Northeast of Brazil in May 2015 before spreading to the entire continent. 28 Since 2016, the Brazilian 
Ministry of Health (BMH) registered ZIKV infections.36,37 Evidence from the BMH displayed ongoing 
CHIKV-ZIKV co-circulation in Brazil and specifically in the Northeast of Brazil (i.e., in 2016, 134 ZIKV 
and 415 CHIKV infections per 100 000 inhabitants registered in the region; with 9 ZIKV and 249 
CHIKV infections per 100 000 inhabitants registered in 2017). 38,39 Of note, the State Health Secretariat 
of Pernambuco and as such Recife's surveillance system made registering ZIKV infection in pregnant 
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women compulsory since December 2015, as a public health response to the observed microcephaly 
outbreak. 21 Thus, the sample testing of this cohort study and the epidemic curve resembles the start 
of the awareness of the potential link between the microcephaly cases and the ZIKV outbreak, hence 
about 9 months after the actual beginning of the ZIKV outbreak. Therefore, despite the timely acting 
of MERG, the depicted peak of this study's temporal epidemiological curve most likely does not reflect 
the true peak of the ZIKV outbreak but should be seen in the light of the new initiation of the 
surveillance system in December 2015. The peak of the temporal epidemiological curve may be an 
artefact of notifications, potentially only picking up the decline of the ZIKV cases after the actual peak 
of the ZIKV outbreak. 40 In line with the temporal findings of our study, the BMH data depicts a decline 
in ZIKV and CHIKV cases between 2016 and 2017. 38,39 Interestingly, the temporal findings of ZIKV 
and CHIKV infections in our study did not follow expected seasonal patterns, being high during the 
dry season of 2015 to 2016 and decreased in the rainy season of 2016. 41 A similar pattern of 
independence from seasonality has been described in two additional studies; a ZIKV study on a 
population sample (n=260) in the city of Paulista in the Recife Metropolitan Region, geographically 
adjacent to our study in 2015/2016 and a DENV time series analysis of surveillance data in the two 
Brazilian cities, Recife and Goiania between 2001 and 2014. 42,43  
 To aid the differential diagnosis of CHIKV and ZIKV infections in a setting with co-circulation, 
an understanding of the frequency of clinical symptoms of CHIKV and ZIKV in comparison to each 
other is important. Clinical symptom frequencies for ZIKV and CHIKV infections have commonly been 
reported in isolation from each other. 44-48 Compared to our study of pregnant women, other studies 
have described more symptomatic ZIKV mono-infections for both pregnant women and the general 
population, with higher symptom frequencies especially reported for joint pain, joint swelling, 
headache, myalgia, and retro-orbital pain. 44,46,48 However, of these studies two reported fever 
frequencies of around 35%, in contrast to Duffy and colleagues and our study, which report about 
double the fever frequency among ZIKV mono-infected cases. 44,46,48 The symptom frequencies of 
CHIKV mono-infections observed in this study are largely supported by the findings of Bagno and 
colleagues, apart from slightly increased frequencies of arthralgia and myalgia, and only a 40% symptom 
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frequency of rash compared to the 100% in our study, as by design the women were recruited into 
our cohort study on the basis of presenting with rash. 49 
 To our knowledge only three studies have reported the clinical presentation of CHIKV mono-
infections compared to that of ZIKV mono-infections. 34,50,51 One study reported similar clinical 
presentation of the CHIKV, DENV and ZIKV infections, however the presented frequencies of clinical 
symptoms caused by ZIKV infections were based on a study population of 31 ZIKV infected cases and 
on CHIKV and DENV study populations of unreported size. 50 Furthermore, this study did not describe 
how the comparison between the frequencies of clinical symptoms of ZIKV infections with that of 
CHIKV and DENV infections was statistically conducted. 44,50 The second study that describes a more 
severe rash and conjunctival hyperaemia for ZIKV cases compared to DENV and CHIKV cases,  also 
did not describe their sample size or their methods used, to assess signs and symptoms, diagnose cases 
or statistically compare frequency of signs and symptoms between ZIKV, CHIKV and DENV infections. 
51 A study by Waggoner and colleagues on 346 patients with suspected arboviral illness in Nicaragua 
reported no significant difference in symptom frequencies between 37 ZIKV cases and 103 CHIKV 
cases, with the exception of rash (91% of ZIKV cases but only in about 56% of CHIKV cases). 34 In 
contrast to previous reports, our results suggest that the clinical presentation of ZIKV mono-infections 
significantly differs from that of CHIKV mono-infections and from that of sequential ZIKV/CHIKV 
infections. Thus, a patient presenting with joint pain, joint swelling, fatigue, retro-orbital pain and 
headache in addition to rash during an onging ZIKV outbreak, should raise attention in a clinician to 
test for a potential CHIKV infection. Thus our findings could impact the follow up and clinical 
management of such patients and thus relieve the public health services economically and capacity-
wise (e.g., by eliminating the need of follow up of pregnant CHIKV cases). 52 
 Our study has strengths and limitations. Compared to other studies reporting on co-
circulation of CHIKV and ZIKV, our study has benefited from a large cohort population with great 
detail of individual characteristics and of reported signs and symptoms. 34,50,51 To the best of our 
knowledge, this is also the first study to compare the symptom frequencies of sequential ZIKV/CHIKV 
infected cases to those of ZIKV mono-infected cases. However, selection bias may have been 
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introduced into the study as only women presenting with rash were recruited into this study, it is 
possible our study results on the clinical presentations of CHIKV and ZIKV are not generalisable 
beyond a ZIKV outbreak setting (i.e., given that rash occurs in around 95% of symptomatic ZIKV 
infected cases versus only 56% of symptomatic CHIKV infected cases). 34,44,46,48 As a consequence, 
ZIKV ascertainment in the epidemiological curve and distribution map may have been higher than 
CHIKV ascertainment. Additionally, information bias may have been introduced during the assessment 
of signs and symptoms of ZIKV and CHIKV infections, as many symptoms were self-reported. 
Nevertheless, as pathogen testing was done after assessment of clinical presentation, any 
misclassification of symptoms was non-differential related to the infection type. Assuming that the 
misclassification is independent of any other measurement error and non-differential with respect to 
other variables, the estimates would be biased towards the null, meaning that any true association 
between signs and symptoms and an infection type may be underestimating. In addition, no formal 
adjustment was made for multiple testing, but if a more stringent confidence level of 99% had been 
used, most of the highlighted results would still have been significant. Due to reported issues of cross-
reactivity of the DENV IgM assays with acute ZIKV sera, we excluded DENV cases from our analysis 
of the clinical presentations. 20 This exclusion of DENV cases from our analysis potentially limits the 
application of our findings on differential diagnosis of ZIKV and CHIKV infections in the event of ZIKV, 
CHIKV and DENV co-circulation. Furthermore, there is a theoretical possibility of the misclassification 
of a ZIKV infected pregnant women as a CHIKV IgM diagnosed pregnant women, i.e., if the blood 
sample was taken in the short timeframe, where ZIKV RNA was no longer present and ZIKV IgM was 
not yet present in the blood sample. The possibility of misclassification also exists for CHIKV mono-
infected women who might have been ZIKV co-infected, as Ximenes and colleagues describe that 
whereas among pregnant women who tested ZIKV PCR positive, 58% did not become IgM or PRNT 
positive. 21 Additionally, of the pregnant women who had no evidence of ZIKV infection 42% were not 
PCR tested. 21 This chance of misclassification however, was counteracted by aiming to take one blood 
sample at each study visit and conducting diagnostic tests for ZIKV infections using serially collected 
samples. 21 Additionally, the clinical presentation assessed in this study may be specific to pregnant 
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women, as immunological alterations have been described in pregnant women potentially leading to 
altered clinical presentations in pregnancy. 53-55 However, studies have described a very similar clinical 
presentation of ZIKV and CHIKV infections in pregnancy in comparison to that of the general 
population, apart from fever which has been described to be a less prevalent symptom of ZIKV 
infection in pregnant women compared to in the non-pregnant population. 44,56-59  
 In conclusion, our findings on the CHIKV-ZIKV co-circulation call for focus on vector control 
as a potential strategy to reduce overall arbovirus transmission in locations and at time points of high 
risk arbovirus transmission, and suggest that CHIKV mono-infections are associated with more 
frequent symptom presentation than ZIKV mono-infections. These differences should be particularly 
in the forefront of clinicians’ thinking when treating patients during ZIKV outbreaks. Despite our 
findings, we believe that relying on diagnosis upon clinical presentation at this point is insufficient to  
differentiate between CHIKV, ZIKV, and sequential ZIKV/CHIKV infections. Therefore, especially in 
pregnant women laboratory testing should be continued to confirm infection type, in order to initiate 
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Table 1: Demographics of the pregnant women cohort in Recife, Pernambuco, Brazil (2015-
2017). 
Characteristics No.   (% or IQR/ ±SD) 
Residency  Recife metropolitan area 550   (79%) 
Outside Recife metropolitan area 144   (21%) 
Age  Median (years) 26     (21,31) 
Ethnicity† Pardo   ("mixed race") 448   (65%) 
Branco ("white") 163   (23%) 
Preto   ("black") 69     (10%) 
Asian 12     (2%) 
Schooling  Median (years) 10     (8,11) 
Highest education†  Primary school (incl. equivalency program) 594   (86%) 
Secondary school (incl. equivalency program) 39     (6%) 
Tertiary school incomplete 38     (6%) 
Tertiary school complete 1       (2%) 
Inhabitants per 
household or house 
Median  3       (2, 4) 
Income (total income 
of people living in the 
house per month)† 
Median (BRL/month) 1140  (877, 1915) 
relative to minimum wage in 2016                                                   
(880.00BRL/Month= 171,97US$/month) 
1.30   (1.0, 2.2) 
x minimum wage  
Comorbidities 
during pregnancy * † 
 
Anaemia 179    (29%) 
Gestational hypertension 131    (20%) 
Diabetes 19      (3%) 
Hypothyroidism 5        (0.7%) 
Chronic kidney disease 2        (0.2%) 
Hypothyroidism 5        (0.7%) 
TORCH diagnostics † Herpes virus IgM 34      (10%) 
Parvovirus IgM 7        (2%) 
Toxoplasma gondii IgM 4        (1%) 
CMV IgM  1        (0.2%) 
Gestational trimester 
when notified with 
rash† 
First 144    (19%) 
Second 226    (38%) 
Third 248    (42%) 
Previous pregnancy 0 261    (38%) 
1 220    (32%) 
2 109    (15%) 
>=3 104    (15%) 
Previous adverse 
pregnancy outcomes †  
Congenital abnormalities 18      (5%) 
Stillbirth 17      (5%) 
Abortions (spontaneous or induced) 137    (38%) 
Mean no. abortion among women  
who had abortions ±SD 
1.3    ± 0.72 
*Reported by pregnant women to have been diagnosed during pregnancy. TORCH- Toxoplasma gondii, 
Other( Syphilis, varicella-zoster, parvovirus, B16), Rubella, Cytomegalovirus (CMV), Herpes virus, Hepatitis 
B&C, Human immunodeficiency virus (HIV) 60. † Missing values: Ethnicity (2); Highest education (7); Income 
(111); Comorbidities: Anaemia (71), Gestational hypertension (23), Diabetes (i.e., before or during 
pregnancy). (3), Epilepsy (1), Chronic heart disease (2), Chronic kidney disease (4); TORCH diagnostics:  
Toxoplasma gondii IgM (258), Parvovirus IgM (249), CMV IgM (210),  Herpes virus IgM (360);  Gestational 
trimester when notified with rash (106);  Previous adverse pregnancy outcomes:  Congenital abnormalities 












   
Table 2: Arbovirus diagnostic test results of pregnant women cohort study in Recife, 
Pernambuco, Brazil  
Arboviruses tested positive Testing methods  No. (%) within cohort 
(nTotal=694) 
ZIKV  ZIKV (PCR, IgM, PRNT)* 305     (44%) 
CHIKV  CHIKV IgM † 145     (21%) 
ZIKV mono infection ZIKV (PCR, IgM, PRNT)* 213    (31%) 
CHIKV mono infection CHIKV IgM 55      (8%) 
sequential ZIKV/CHIKV 
infection 
ZIKV (PCR, IgM, PRNT)*                         
and CHIKV IgM 
58 (8%) 
Zika virus (ZIKV), Chikungunya virus (CHIKV), *A panel of virologists, epidemiologists and 
statisticians agreed upon each individual case of ZIKV positive diagnosis, assessing correlation of 
qRT-PCR, IgM and PRNT results. 21 † The CHIKV IgM diagnostic tests can detect a recent CHIKV 
infection (i.e., 3 to 4 days and up to 2 months  following symptom onset). 25 The 305 ZIKV infections 
and 145 CHIKV infections, result from the inclusion of cases with additional recent DENV infections. 
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Table 3: Prevalence of signs and symptoms of ZIKV mono- vs CHIKV mono-infected pregnant women within the cohort. Crude and adjusted 
analysis of association of signs and symptoms with ZIKV and CHIKV mono-infection (nTotal=268). 
 




p-value OR  
adjusted for 





%  (95% CI) † No. of 
nTotal 55 
%  (95% CI)**   
Fever 167  78% (72%- 84%) 44  80%  (67%- 90%) 1.08    (0.50- 2.33)   0.84 1.09   (0.51- 2.37) 0.82 
Joint pain (arthralgia) 64  30% (24%- 37%) 31  56%  (42%- 70%) 3.01    (1.63- 5.57) <0.001 2.98   (1.61- 5.28) 0.001 
Headache 55  26% (20%- 32%) 24  44%  (30%- 58%) 2.30    (1.24- 4.29) 0.0090 2.25   (1.20- 4.20) 0.011 
Muscle pain (myalgia) 54 25% (19%- 32%) 22  40%  (27%- 54%) 1.95    (1.04- 3.64) 0.037 1.93   (1.03- 3.62) 0.041 
Back ache 43  20% (15%- 26%) 18  33%  (21%- 47%) 1.97    (1.02- 3.82) 0.044 1.92   (0.99- 3.73) 0.054 
Fatigue 37  17% (13%- 23%) 19  35%, (22%- 49%) 2.51    (1.30- 4.86) 0.0060 2.46   (1.26- 4.78) 0.008 
Joint swelling (arthritis) 32  15% (10%- 21%) 19  35%  (22%- 49%) 2.97    (1.52- 5.82) 0.0020 2.87   (1.45- 5.65) 0.0020 
Nausea 24  11% (7%– 16%) 11  20%  (10%- 33%) 1.95    (0.89- 4.29) 0.096 2.04   (0.92- 4.52) 0.078 
Photophobia 19  9%   (6%-14%) 7  13%  (5%- 25%) 1.54    (0.61- 3.88) 0.36 1.59   (0.63- 4.02) 0.33 
Retro-orbital pain 18  8%   (5%-13%) 11 20%  (10%- 33%) 2.80    (1.23- 6.38) 0.014 2.73   (1.19- 6.24) 0.018 
Abdominal pain 18  8%   (5%-13%) 7  13%  (5%- 25%) 1.56    (0.62- 4.00) 0.35 1.67   (0.66- 4.28) 0.28 
Eye Redness 18  8%   (5%-13%) 6  11%  (4%- 22%) 1.33    (0.50- 3.55) 0.56 1.33   (0.50- 3.55) 0.57 
* Cough, sore throat, runny nose, pruritus, secretion of eyes were also reported, however had an overall symptom prevalence with less than 5% in either of the 
comparison groups, thus no likelihood ratio test was done, due to too low power. Missing values (n) for ZIKV infected: fever (5), muscle pain (6), joint pain (6), joint 
swelling (6), retro-orbital pain (7), eye redness (7), photophobia(6), headache (5), nausea (6),  back ache (5),   **Missing values (n) for CHIKV infected: fever (1), muscle 
pain (1),  joint pain (1), joint swelling (1), retro-orbital pain (3), eye redness (2), photophobia(3), headache (2), nausea (1), back ache (2).  †† By logistic regression. 
ZIKV-mono-infection group would be the reference group to calculate OR.   
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Table 4: Prevalence of signs and symptoms of ZIKV mono- vs sequential ZIKV/CHIKV infection pregnant women cohort. Crude and adjusted 
analysis of association of signs and symptoms with ZIKV and sequential ZIKV/CHIKV infections (nTotal=271). 
 





(95% CI) †† 
p-value OR  
adjusted for 





% (95% CI)† No. of 
 nTotal 58 
% (95% CI)**   
Fever 167  78% (72%- 84%) 46 79%  (67%- 89%) 1.03      (0.50- 2.16) 0.95 1.10     (0.54- 2.27) 0.791 
Joint pain (arthralgia) 64  30% (24%- 37%) 26 45%  (32%- 59%) 1.87      (1.03- 3.41) 0.040 1.85     (1.01- 3.38) 0.050 
Headache 55  26% (20%- 32%) 23  40%  (27%- 53%) 1.88      (1.02- 3.47) 0.043 1.82     (0.98- 3.37) 0.060 
Muscle pain (myalgia) 54 25% (19%- 32%) 22  38%  (26%- 52%) 1.78      (0.96- 3.30) 0.067 1.76     (0.95- 3.28) 0.073 
Back ache 43  20% (15%- 26%) 19 33%  (21%- 46%) 1.92      (1.01- 3.65) 0.048 1.84     (0.96- 3.52) 0.066 
Fatigue 37  17% (13%- 23%) 21  36%  (24%- 50%) 2.70      (1.42- 5.13) 0.003 2.63     (1.38- 5.03) 0.003 
Joint swelling (arthritis) 32  15% (10%- 21%) 10  17%  (9%- 30%) 1.16      (0.53- 2.53) 0.71 1.14     (0.52- 2.50) 0.74 
Nausea 24  11% (7%– 16%) 14  24%  (14%- 37%) 2.48      (1.19- 5.19) 0.016 2.54     (1.21- 5.35) 0.014 
Photophobia 19  9%   (6%-14%) 7  12%  (5%-23%) 1.39      (0.55- 3.47) 0.49 1.42     (0.56- 3.58) 0.46 
Retro-orbital pain 18  8%   (5%-13%) 6  10%  (4%- 21%) 1.23      (0.46- 3.26) 0.68 1.21     (0.45- 3.23) 0.70 
Abdominal pain 18  8%   (5%-13%) 6  10%  (4%- 21%) 1.24      (0.47- 3.27) 0.67 1.31     (0.49- 3.51) 0.59 
Eye Redness 18  8%   (5%-13%) 7  12%  (5%-23%) 1.46      (0.58- 3.49) 0.42 1.42     (0.56- 3.61) 0.46 
*Cough, sore throat, runny nose, pruritus, secretion of eyes were also reported, however had an overall symptom prevalence with less than 5% in either of the 
comparison groups, thus no likelihood ratio test was done, due to too low power. † Missing values (n) for ZIKV infected: fever (5), muscle pain (6), joint pain (6), joint 
swelling (6), retro-orbital pain (7), eye redness (7), Photophobia(6), Headache (5), Nausea (6),  back ache (5),  **Missing values (n) for ZIKV and recently CHIKV 
infected: fever (1), muscle pain (1),  joint pain (1), joint swelling (1), retro-orbital pain (1), eye redness (1),  photophobia(1), headache (1), nausea (1),  back ache (1).  




Figure 1: Epidemiological curve depicting all notified pregnant women that tested positive 
for ZIKV (blue) and CHIKV(yellow) and all pregnant women that were notified with rash 
(black dashes) in the cohort study in Recife, Pernambuco in Brazil (December 2015 - July 
2017). Zika virus (ZIKV), Chikungunya virus (CHIKV), Epidemiological week (EW), Epidemiological 
month (EM), Epidemiological year (EY), the blue lines above the epidemiological months indicates the 
months of the rainy season in Recife, Pernambuco, Brazil. 26 The black arrow indicates the beginning of 
the surveillance system. 
 
Figure 2:  Map of all notified pregnant women that tested positive for ZIKV (blue) (n=108) 
and CHIKV (yellow) (n=34) and for ZIKV and CHIKV (green) (n=38) in the cohort study 
in the city of Recife, Pernambuco in Brazil (December 2015 - July 2017). Recife is located 
in the East of Pernambuco, and Pernambuco is located in the North-East of (small map 











































Figure 5: Epidemiological curve depicting all notified pregnant women that tested positive for 
ZIKV (blue) and CHIKV(yellow) and all pregnant women that were notified with rash (black 
dashes) in the cohort study in Recife, Pernambuco in Brazil (December 2015 - July 2017). 
Zika virus (ZIKV), Chikungunya virus (CHIKV), Epidemiological week (EW), Epidemiological month (EM), 
Epidemiological year (EY). The blue lines above the epidemiological months indicates the months of the 




























Figure 2:  Map of all notified pregnant women that tested positive for ZIKV (blue) (n=108) 
and CHIKV (yellow) (n=34) and for ZIKV and CHIKV (green) (n=38) in the cohort study 
in the city of Recife, Pernambuco in Brazil (December 2015 - July 2017). Recife is located 
in the East of Pernambuco, and Pernambuco is located in the North-East of (small map 
at the top left). Zika virus (ZIKV), Chikungunya virus (CHIKV). 
Supplementary appendices of Paper II is in the APPENDIX III (p126) 
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3. CHAPTER III: DISCUSSION 
3.1 Overview 
 The overall aim of this study was to investigate co-circulating arboviruses in Latin America in 
regard to co-infection and differential diagnosis based on clinical presentation, with a focus on the 
arboviruses of greatest current public health concern in Latin America: CHIKV, DENV and ZIKV. This 
was done by first systematically reviewing the literature on the frequency and clinical presentation of 
ZIKV co-infections (paper 1) and by second describing the clinical presentation of ZIKV and CHIKV 
using data from a pregnant women cohort that presented with rash in Recife, Pernambuco, Brazil 
between 2015 and 2017 (paper 2).        
 This chapter contains two main sections. First, I summarized the main findings of each of the 
two research papers that formed the basis of this research and described their limitations. Second, I 
discuss the public health implication of this work alongside recommendations for future research. 
3.2 Summary and interpretation of main findings 
The unknown frequency of arbovirus co-infections and their impact on the clinical 
presentation and the accurate discrimination between arbovirus infections are two central challenges 
of co-circulating arboviruses in Latin America. The study's systematic review on ZIKV co-infections 
found that the most commonly reported ZIKV co-infections were with the co-circulating arboviruses 
CHIKV and DENV, which occurred in specific populations and epidemiological contexts in up to half 
of ZIKV infections. In contrast to findings of previous studies on arbovirus co-infections, this work 
suggests co-infections do not distinctly change the generally mild clinical presentation of uncomplicated 
ZIKV disease, as defined by the WHO1-3. However, the available evidence for this systematic review, 
including the methods used to generate the data, was insufficient to rule out the possibility that the 
clinical spectrum of ZIKV was influenced by co-infection, in particular as the data lacked a 
representative sample of ZIKV mono-infections for an appropriate comparison to ZIKV co-infections. 
Hence, this work was unable to assess whether co-infections lead to an increased incidence of ZIKV-
related complications. Nevertheless, to our knowledge, this is the first study to systematically review 
the frequency and clinical presentation of ZIKV co-infections, and therefore represents important 
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groundwork for future research.                                                        
 To facilitate the accurate differentiation between arbovirus infections at the stage of symptom 
presentation in a setting of arbovirus co-circulation, I believe an understanding of the frequency of 
arboviruses’ clinical symptoms in comparison to each other is important. As mentioned, research to 
date has mainly reported the respective clinical presentation of CHIKV, ZIKV and DENV infections in 
isolation from each other, and only three studies have reported a comparison of the clinical 
presentation of CHIKV mono-infections and ZIKV mono-infections, although with limited sample sizes 
and limited explanation of quantitative statistical methods used4-12.  
Accordingly, this research set out to address these gaps in knowledge. First, this study's 
descriptive study described the temporal and geographic co-circulation of CHIKV in a pregnant 
woman cohort during the outbreak and decline of ZIKV in Recife, Pernambuco, Brazil between 2015 
and 2017. Second, in contrast to previous research, the work demonstrated that, in comparison to 
ZIKV mono-infected pregnant women, CHIKV mono-infected pregnant women presented significantly 
more frequently with symptoms, such as joint pain, joint swelling, fatigue, retro-orbital pain and 
headache. Additionally, pregnant women with sequential ZIKV/CHIKV infections presented more 
frequently with symptoms compared to pregnant women with ZIKV mono-infections, with differences 
most apparent for fatigue, nausea, and joint pain. Hence, there was substantial overlap between the 
symptoms identified as more common in CHIKV mono-infected than in ZIKV mono-infected, and 
those more common in sequential ZIKV/CHIKV infected than in ZIKV mono-infected women, with 
the exceptions of joint swelling and retro-orbital pain. This overlap suggests that certain clinical 
features, in particular joint pain and fatigue, are strongly associated with CHIKV both for sequential 
or mono-infections and should be at the forefront of the clinician's thinking when treating patients in 
a setting of co-circulating arboviruses. However, the overlap also suggests that if CHIKV is suspected, 
ZIKV cannot be ruled out. To note, this is the first study to our knowledge that compares symptom 
frequency of sequentially ZIKV/CHIKV infected, in addition to CHIKV mono-infected, to ZIKV mono-
infected cases. 
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3.3 Limitations of main findings 
 Specific strengths and limitations have been discussed in each paper. In addition, concerning 
the systematic review, it is likely that not all globally existing ZIKV co-infection types and associated 
clinical outcomes have yet been reported and that the ZIKV co-infection frequencies overall are 
underreported.  Different causes might have led to the limited data available. When identifying ZIKV 
co-infections, there might have been economic and practical limitations (i.e., as methods are expensive 
and need sterile laboratory conditions and working expertise) preventing exhaustive testing and qRT-
PCR testing of all potential co-infecting pathogens. In addition, information bias might have been 
introduced when ZIKV co-infection types were reported, such as the clinician choosing what 
pathogens to test for (i.e., testing by diagnostic suspicion). Diagnostic suspicion in pathogen testing 
could be either based on the patient’s clinical presentation and geographic pathogen predominance 
(e.g., patient presented with hemodynamic instability in Puerto Rico, hence the clinician tested for 
arboviruses and Leptospira spp.)13 or the pregnant state of a female patient, which encourages the 
testing for any pathogen introducing risk in pregnancy (e.g., testing for ZIKV and Toxoplasma gondii)14. 
Thus, diagnostic suspicion inherently risks overlooking other co-infecting pathogens. Furthermore, as 
the study populations of all studies included in this systematic review only detected symptomatic cases, 
selection bias might have additionally been introduced, which may have led to the overreporting of 
the proportion of symptomatic ZIKV co-infections. Additionally, it is likely that the lack of reported 
asymptomatic ZIKV co-infection might have led to an overall underreporting of ZIKV co-infections. 
Diagnostic algorithms, such as that of the Brazilian SINAN (i.e., Brazilian Information System for 
Notifiable Diseases) also lead to a continuing underreporting of arbovirus co-infections, as after one 
arbovirus diagnosis is confirmed, further testing for co-infecting agents is not encouraged15. Publication 
bias (i.e., systematic differences between published and unpublished evidence) might have additionally 
impacted the results of the systematic review. For example observational studies without significant 
findings may be less represented in the appraised literature 16. Additionally, although useful for 
describing more severe and rare complications which would otherwise require large sample sizes to 
detect, case reports are typically biased towards unusual or severe disease presentations. As this study 
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aimed to investigate the most frequently reported ZIKV co-infection types and their potential to cause 
more severe clinical outcomes of ZIKV infections, the above mentioned limitations are important to 
note, however, they do not undermine the value of the findings on ZIKV co-infections with CHIKV 
and DENV in this systematic review. Overall, an accurate estimate of the prevalence of ZIKV co-
infections in different locations would be of public health relevance since it would enable the 
assessment of the overall magnitude of the potential impact of ZIKV co-infections, especially in the 
context of ZIKV associated adverse birth and other adverse clinical outcomes.     
 As described in the introduction, the laboratory diagnosis of arboviruses is complex and 
presents a challenge for research on arboviruses, especially in a setting of arbovirus co-circulation. 
This includes the very short time window for accurate arboviral nucleic acid testing, which affects 
CHIKV, DENV and ZIKV infections as well as the difficult issue of serological cross-reactivity between 
flaviviruses, which makes the differentiation of DENV and ZIKV by ELISA assays challenging17-19. Due 
to this obstacle, the main limitation of the study's descriptive work was the exclusion of potentially 
DENV infected pregnant women from the comparison of clinical presentations of arbovirus infections. 
This could be problematic because although the number of potentially DENV infected women in this 
pregnant women cohort was low (i.e., about 9% of the total pregnant women cohort), a setting with 
exclusive co-circulation of ZIKV and CHIKV is unlikely, because DENV transmission is mostly endemic 
or epidemic in areas of ZIKV and CHIKV transmission20,21.  
 Nevertheless, despite this work not having investigated the clinical presentation of CHIKV and 
ZIKV infections in comparison to DENV infections, previous studies have compared the clinical 
presentation of CHIKV to DENV infections and ZIKV to DENV infections 22-28. The most well-
powered of these studies was conducted over 3 years (i.e., 2012 to 2015) in Puerto Rico on about 
9000 patients with acute febrile illness (AFI), with the aim to distinguish CHIKV from DENV infected 
and other AFI cases based on robust clinical indicators23. In this study 1499 laboratory confirmed 
CHIKV infected cases were compared to 685 laboratory confirmed DENV infected cases23.  
Interestingly, consistent with our findings on the strong association of joint pain with CHIKV infection, 
the Puerto Rican study found that swollen joints, joint pain, skin rash, bleeding and irritability were 
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the most significant positive predictors of a CHIKV infection when comparing CHIKV to DENV 
infections23.  In contrast, in the same study a higher proportion of DENV than CHIKV infected cases 
presented with headache, chills, dizziness, retro-orbital pain, GI symptoms (e.g., nausea, abdominal 
pain, diarrhoea, vomiting, anorexia), poor circulation, moderate hemoconcentration, severe 
hemoconcentration and leukopenia180. Additionally, another study from Singapore compared the 
clinical presentation of 34 ZIKV infected cases with that of 87 DENV infected cases24. The study 
identified the presence of conjunctivitis and a normal platelet and monocyte count as positive 
predictors for ZIKV infection24. Despite the low sample size and the study location in Singapore, they 
argue that this definition has 88% sensitivity and 93% specificity and exceeding accuracy compared to 
WHO's and CDC's definition, when distinguishing ZIKV from DENV infections24. DENV infected cases 
in the latter study were also described to have presented more frequently with fever and headache 
than ZIKV infected cases 24. Thus, evidence suggests that the clinical presentation of DENV infected 
cases can be distinguished from ZIKV and CHIKV infected cases. However, the main clinical predictors 
of CHIKV, DENV and ZIKV infections in comparison to each other still have to be investigated.  
 Furthermore, as resources were limited for qRT-PCR testing of CHIKV and DENV infections 
in my study I was not able to investigate whether arbovirus co-infections (i.e., ZIKV/CHIKV, 
ZIKV/DENV, CHIKV/DENV co-infections) presented with a different clinical presentation to arbovirus 
mono-infection. However, a potential different clinical presentation of arbovirus co-infections should 
be at the forefront of clinician's minds and should be investigated in future studies.  
 Finally, the findings of the descriptive study may be limited in generalizability. As mentioned 
above, this may include factors such as having solely included: a) women presenting with rash                 
(i.e., upon a ZIKV case definition and hence limiting the study's findings to a ZIKV outbreak setting),  
b) pregnant women (i.e., potentially immunologically altered and exclusively female), c) a population 
with predominant pre-existing DENV immunity (i.e., potentially influencing the clinical presentation of 
ZIKV infection29)30-32 and d) by only focusing on arbovirus diseases.   
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3.4 Implications and recommendations 
 Not only did the systematic review contribute to important groundwork on ZIKV co-
infections, it also highlighted important knowledge gaps on ZIKV co-infections to be prioritized in 
future research. Overall, our evidence suggests that DENV and CHIKV have been the most frequently 
reported ZIKV co-infecting pathogens. Thus, from the perspective of public health relevance, I 
recommend that future research should be approached in two steps and specifically aimed at ZIKV 
co-infections with CHIKV and DENV. First, robust estimates of ZIKV/CHIKV, ZIKV/DENV and 
ZIKV/CHIKV/DENV co-infection frequencies among ZIKV infected should be assessed in cohort 
studies in different locations in order to estimate the actual worldwide burden of ZIKV co-infections 
and their potential clinical impact. Second, these cohort studies should serve to precisely define the 
clinical spectrum and the frequency of complications associated with ZIKV co-infections. Here, in 
particular neurological complications and adverse birth outcomes should be investigated. These 
research steps are required to estimate the impact of arbovirus co-infections in order to make public 
health policy recommendations if needed, such as changing testing algorithms to enhance the detection 
of arbovirus co-infections and thereby reducing potential associated adverse outcomes.  
 To note, there are two ongoing prospective cohort studies on ZIKV co-infections. The first 
cohort study specifically investigates ZIKV/HIV co-infections, with the aim to determine the risk of 
adverse maternal and child outcomes associated with ZIKV/HIV co-infected pregnant women 
compared to ZIKV mono-infected pregnant women across clinical sites in the US, Puerto Rico and 
Brazil (NCT03263195)33. The second cohort study is also an ongoing multi-country, prospective 
cohort study (i.e., in ZIKV endemic regions of Brazil (4 sites), Colombia, Guatemala, Nicaragua, Puerto 
Rico (2 sites), and Peru), called the Zika in infant and pregnancy (ZIP) study (NCT02856984), that 
aims to recruit 10 000 pregnant women in order to evaluate the association between ZIKV and 
pregnancy, neonatal, and infant outcomes34,35. One of the ZIP study's secondary objectives is to 
determine whether co-infections contribute to ZIKV associated adverse birth outcomes34.  
 Diagnosing arbovirus infection early in the clinical course is challenging. Nevertheless, it is 
important in order to guide patient management and administer guidance for timely follow up, 
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especially for patients during pregnancy and patients who may develop post-acute and/or chronic 
disease. The early diagnosis of CHIKV mono-infection in pregnancy may relieve women of the 
psychological stress of expecting adverse birth outcomes associated with maternal ZIKV infections in 
pregnancy. It will also impact on the follow up and clinical management of such patients and thus assist 
the public health services financially and capacity-wise36. In contrast, identifying ZIKV infections early 
in pregnancy will facilitate access to the required follow-ups.     
 Although laboratory diagnosis of arbovirus infections is important for patient care and 
improving public health, it is often not available or is time-consuming. Thus, in resource poor settings 
and outbreak scenarios, arbovirus diagnosis often relies on the identification of clinical features, usually 
consistent with the WHO case definition, which has been described to be of unknown sensitivity and 
specificity as well as to vary by age groups and timing of specific sign and symptom onset after 
infection37-39. Therefore, our findings on distinguishing CHIKV and ZIKV mono-infections upon clinical 
presentation in pregnant women may aid healthcare workers to identify CHIKV infected cases in a 
ZIKV outbreak and potentially improve patient outcomes. Nevertheless, the similar clinical 
presentation of CHIKV infected and sequentially ZIKV/CHIKV infected pregnant women, displays that 
ZIKV infection cannot be ruled out a when a CHIKV infection is diagnosed. Furthermore, the early 
identification of symptomatic patients with acute arbovirus infections may also help to further limit 
transmission of arboviruses within communities and households. Thus, to improve evidence on 
distinguishing CHIKV, DENV and ZIKV infections through the identification of clinical features, future 
cohort studies, such as the above described ZIP study,  are needed with greater sample sizes, with 
study populations including all age groups from both sexes and in areas where all three diseases are 
common34. Such studies should also have the possibility of identifying symptom outcomes together 
with date post symptom onset. Individual participant data meta-analysis (IPD-MA), such as the ZIKV 
IPD-MA, could additionally be utilized to compare the data of different cohort studies on ZIKV co-
infections40.  
 While we could target arbovirus disease individually by developing better diagnostics, 
treatments and vaccinations, we could also target arbovirus diseases all at once by targeting their 
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vectors. This  approach, however, remains a great challenge throughout the world. To date, our 
resources of vector control span from self-protection against mosquito bites to community-based 
mosquito control. Arbovirus disease control programms should strengthen health education to 
stimulate self-protection against mosquito bites, which currently include using air conditioning, 
screens, wearing long trousers and sleeves, and using mosquito repellent when outdoors. 
Nevertheless, there is little evidence on the efficacy of self-protection, and it has been reported to 
require extensive health education for appropriate use as well as be of limited use due its cost and 
acceptability in constant use. Control tools such as insecticide treated bed nets, used to prevent the 
transmission of malaria, are not efficacious for the control of CHIKV, DENV and ZIKV transmission, 
as Aedes aegypti is a day biting vector. Common mosquito control measures include chemical pesticides 
and mechanical breeding-site reduction (i.e., destruction of breeding sites, such as stored water), but 
these measures have to date failed to prevent arbovirus transmission in most parts of Latin America. 
 Alternative mosquito control methods are currently being tested in different locations around 
the world, including, for example, Wolbachia infection in mosquitos and RIDL (Release of Insects with 
Dominant Lethality)41. Mathematical models, developed to predict the effect of Wolbachia mosquito 
strains on DENV transmission, have estimated that these strains could achieve a 66%–75% reduction 
in the basic reproduction number, R0.42 Additionally, RIDL have achieved a 95% reduction in local 
Aedes populations in Brazil41. As these alternative mosquito control measures are currently still being 
trialled for safety and ecosystem influences, most affected governments have not yet implemented 
them. 
 To note, increasing evidence suggests that tropical arbovirus infections, such as those caused 
by CHIKV, DENV and ZIKV, mainly occur in poor rural and urban settings and disproportionally affect 
low-income populations43-45. Additionally, arboviral disease outcomes can contribute to poverty by 
causing long-lasting sequelae and maintaining a cycle of disease, poverty and inequity of access to 
healthcare44. Poverty alone does not promote arboviral outbreaks; however, a community’s inability 
to provide adequate vector control, housing conditions, water supplies, reduced crowding and 
occupational exposures can perpetuate the spread of these diseases44. This highlights that multiple 
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factors, such as health care education, environmental factors, income inequality, policy making and 
cultural behaviour, impact on the ongoing co-circulating and transmission of arboviruses and thus 
future research is needed to understand the correlation of these multiple factors to effectively 
eliminate arboviral co-circulation and consequently human transmission and infection. 
3.5 Conclusion 
 In summary, until mosquito control measures are effective enough to prevent arbovirus 
transmission, the clinical management of CHIKV, DENV and ZIKV infected patients remains essential. 
Therefore, the findings presented in this research on ZIKV co-infections and the clinical presentation 
of ZIKV and CHIKV infected pregnant women contribute to improved patient management and are 
thus, of great public health relevance. Nevertheless, this work also highlights the need for more 
research and more understanding and discussion about the co-circulation of arboviruses and the 
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APPENDIX II PAPER II SUPPLEMENTARY MATERIALS 
Supplementary table 1: Odds ratio of being CHIKV mono-infected compared to ZIKV mono- infected, of significantly common symptoms of CHIKV mono-infected pregnant 
women were combined in a model.  
 
Symptom Variable 
OR of being CHIKV infected 
vs. ZIKV infected 95 % CI p-value* 
Joint pain joint pain 3.01 (1.64- 5.52) 0.0001 
Joint pain + joint swelling  joint pain 2.3 (1.13- 4.73) 0.022 
  joint swelling 1.78 (0.81- 3.94) 0.153 
Joint pain + joint swelling+ fatigue joint pain 2.13 (1.00- 4.52) 0.49 
  joint swelling 1.63 (0.71- 3.75) 0.246 
  fatigue 1.33 (0.60- 2.95) 0.54 
Joint pain + fatigue joint pain 2.52 (1.26- 5.02) 0.009 
  fatigue 1.53 (0.71- 3.25) 0.273 
 
Joint pain + joint swelling + fatigue +headache joint pain 2.18 (0.94- 5.05) 0.07 
  joint swelling 1.63 (0.71- 3.78) 0.244 
  fatigue 1.33 (0.59- 3.07) 0.476 
  headache 0.15 (0.41- 2.23) 0.913 
      
Joint pain + headache joint pain 2.76 (1.27- 6.00) 0.01 
  headache 1.15 (0.52- 2.54) 0.731 
      
Fatigue + headache fatigue 1.89 (0.87- 4.12) 0.107 
  headache 1.64 (0.79- 3.40) 0.181 
      
Fatigue +joint pain+ headache fatigue 1.52 (0.69- 3.37) 0.299 
  joint pain 2.51 (1.13- 5.58) 0.024 
  headache 1.00 (0.44- 2.32) 0.988 






Supplementary Figure 1: Presence of one symptom being associated with the presence of another symptom. In A association of symptom presentation is presented for only 
ZIKV cases and in B association of symptom presentation is presented only for CHIKV cases. Association was tested using a chi-squared test. Dark red depicted a p-value of <0.001, pink 
depicted a p-value of <0.05 and white depicted no significant p-value.  
A B 
